News Release
June 1, 2015
EMD Millipore Launches Cellvento™ CHO Cell Culture Media Platform for Optimized Cell Growth and Productivity
- Media and companion feeds for batch, fed-batch and perfusion applications
- Supports CHO-S, CHO-DHFR negative and CHO-K1 suspension cell types
- Formulated to provide superior performance in cell growth and productivity
June 1, 2015, Billerica, MA — EMD Millipore, the Life Science division of Merck KGaA, Darmstadt, Germany, today announced the launch of its Cellvento Cellvento™ CHO platform of cell culture media and companion feed formulations for batch, fed-batch and perfusion applications. Available in liquid and powder form, the chemically defined, non-animal-origin media deliver superior cell growth and productivity for various CHO cell types used in biopharmaceutical development and manufacturing.
The Cellvento™ CHO platform includes cell line and process-specific media and feed compositions, allowing selection of the optimal media formulation for a given application. The range of products also offers customers the flexibility to choose the most suitable product to achieve the best possible performance results for their specific cell line.
The platform provides a variety of formulations designed to meet the needs of CHO-S, CHO-DHFR negative and CHO-K1 suspension cell types. All formulations offer excellent powder homogeneity and consistency, resulting in strong lot-to-lot reproducibility. The media are supported by comprehensive regulatory information on their manufacture, characterization and control.
“Biopharmaceutical manufacturers require cell culture media that will deliver the most robust product yield, quality and consistency,” said Andrew Bulpin, executive vice president of EMD Millipore, Process Solutions Business Area. “The Cellvento™ CHO platform offers a variety of formulations, all backed by EMD Millipore’s strong chemical, raw material and regulatory expertise. This range of options ensures customers have the flexibility to select the best media for their specific process, optimizing their production and ultimately accelerating time to market.”
The Cellvento™ CHO platform includes the following media:
| Medium | Cell line | Use and application |
|---|---|---|
| Cellvento™ CHO-100 | CHO-S | Growth medium for batch and perfusion |
| Cellvento™ CHO-110 | CHO-DHFR negative | Growth medium for batch and perfusion |
| Cellvento™ CHO-200 | CHO-S | Production medium for fed-batch |
| Cellvento™ CHO-210 | CHO-DHFR negative | Production medium for fed-batch |
| Cellvento™ CHO-220 | CHO-K1 | Production medium for fed-batch |
The production media all have companion feed formulations to extend the cell production phase and maximize yields.
For more information about the Cellvento™ CHO platform, please visit www.emdmillipore.com/cellvento.
About EMD Millipore
EMD Millipore is the U.S. Life Science subsidiary of Merck KGaA, Darmstadt, Germany. As part of the global Life Science business of Merck KGaA, Darmstadt, Germany, EMD Millipore offers a broad range of innovative, performance products, services and business relationships that enable our customers' success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the life science tools industry, the Life Science business of Merck KGaA, Darmstadt, Germany, serves as a strategic partner to customers and helps advance the promise of life science. Headquartered in Billerica, Massachusetts, the global business has around 10,000 employees, operations in 66 countries and 2014 revenues of €2.7 billion.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials – and generated sales of € 11.3 billion in 2014. Around 39,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck KGaA, Darmstadt, Germany, is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day.
For more information, please visit www.emdgroup.com.